{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPC1063&page=2",
    "query": {
      "intervention": "RPC1063",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPC1063&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T01:54:39.096Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04528290",
      "title": "A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-10-07",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04528290"
    },
    {
      "nct_id": "NCT03694119",
      "title": "Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Phenelzine",
          "type": "DRUG"
        },
        {
          "name": "Tyramine",
          "type": "DRUG"
        },
        {
          "name": "Phenelzine placebo",
          "type": "DRUG"
        },
        {
          "name": "ozanimod placebo",
          "type": "DRUG"
        },
        {
          "name": "ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 92,
      "start_date": "2018-07-24",
      "completion_date": "2019-01-08",
      "has_results": false,
      "last_update_posted_date": "2019-07-19",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03694119"
    },
    {
      "nct_id": "NCT02531126",
      "title": "An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "RPC1063",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 877,
      "start_date": "2015-12-02",
      "completion_date": "2024-12-19",
      "has_results": true,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02531126"
    },
    {
      "nct_id": "NCT06181630",
      "title": "A Lactation Study in Women Receiving Treatment With Ozanimod",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lactating Women",
        "Breastfed Infants"
      ],
      "interventions": [
        {
          "name": "Breast milk, plasma, and blood samples",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2025-11-15",
      "completion_date": "2026-12-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06181630"
    },
    {
      "nct_id": "NCT05605782",
      "title": "A Post-Authorization, Long-term Study of Ozanimod Real-world Safety",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9000,
      "start_date": "2021-09-02",
      "completion_date": "2033-07-26",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05605782"
    },
    {
      "nct_id": "NCT05470985",
      "title": "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 5,
      "start_date": "2023-08-22",
      "completion_date": "2024-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 19,
      "location_summary": "Garden Grove, California • Los Angeles, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470985"
    },
    {
      "nct_id": "NCT05688436",
      "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Diroximel Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer acetate",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Natalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ocrelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon beta-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ponesimod",
          "type": "DRUG"
        },
        {
          "name": "Siponimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1178,
      "start_date": "2021-09-24",
      "completion_date": "2031-01-17",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05688436"
    },
    {
      "nct_id": "NCT06334094",
      "title": "Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-06-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334094"
    },
    {
      "nct_id": "NCT03624959",
      "title": "Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Gemfibrozil",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-06-20",
      "completion_date": "2018-08-10",
      "has_results": false,
      "last_update_posted_date": "2019-05-30",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03624959"
    },
    {
      "nct_id": "NCT02576717",
      "title": "A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "RPC1063",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2494,
      "start_date": "2015-10-16",
      "completion_date": "2023-01-05",
      "has_results": true,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-09-17T01:54:39.096Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576717"
    }
  ]
}